Correction to "Results From a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ANX005, a C1q Inhibitor, in Patients With Guillain-Barré Syndrome"
- PMID: 40375604
- PMCID: PMC12230543
- DOI: 10.1111/jns.70024
Correction to "Results From a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ANX005, a C1q Inhibitor, in Patients With Guillain-Barré Syndrome"
Erratum for
-
Results From a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ANX005, a C1q Inhibitor, in Patients With Guillain-Barré Syndrome.J Peripher Nerv Syst. 2025 Mar;30(1):e70009. doi: 10.1111/jns.70009. J Peripher Nerv Syst. 2025. PMID: 40000167 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources